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Abstract: Molecular etiology of thyroid cancers has been widely studied, and several 
molecular alterations have been identified mainly associated with follicular and papillary 
histotypes. However, the molecular bases of the complex pathogenesis of thyroid carcinomas 
remain poorly understood. HOX genes regulate normal embryonic development, cell 
differentiation and other critical processes in eukaryotic cell life. Several studies have 
shown that HOX genes play a role in neoplastic transformation of several human tissues. In 
particular, the genes belonging to HOX paralogous group 13 seem to hold a relevant role in 
both tumor development and progression. We have identified a significant prognostic role 
of HOX D13 in pancreatic cancer and we have recently showed the strong and progressive 
over-expression of HOX C13 in melanoma metastases and deregulation of HOX B13 
expression in bladder cancers. In this study we have investigated, by immunohistochemisty 
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and quantitative Real Time PCR, the HOX paralogous group 13 genes/proteins expression 
in thyroid cancer evolution and progression, also evaluating its ability to discriminate between 
main histotypes. Our results showed an aberrant expression, both at gene and protein level, 
of all members belonging to paralogous group 13 (HOX A13, HOX B13, HOX C13 and 
HOX D13) in adenoma, papillary and follicular thyroid cancers samples. The data suggest 
a potential role of HOX paralogous group 13 genes in pathogenesis and differential diagnosis 
of thyroid cancers. 
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1. Introduction 
Thyroid tumors are the most common tumors of the endocrine system (1% of all cancers). 
Approximately 94% of thyroid cancers are well-differentiated forms (papillary and follicular), 5% are 
represented by medullary carcinoma and the remaining 1% anaplastic carcinomas [1]. In recent years 
the progressive knowledge of the molecular mechanisms involved in thyroid transformation have 
allowed the association of alterations of specific markers to several thyroid tumor histotypes [2] permitting 
the formulation of a rather accurate model of tumorigenesis, although not yet fully defined [3]. 
Rearrangements of RET, for example, are specific for papillary carcinoma [4], and mutations of B-RAF 
are also associated to a more aggressive course [5]. However, the prognosis of thyroid cancer remains 
unpredictable, thus the identification of new biological markers are needed in addition to already 
known molecules, to correctly stratify patients at risk of recurrence and progression.  
HOX genes regulate normal embryonic development, cell differentiation and other critical processes 
in eukaryotic cell life. Several studies have demonstrated that HOX genes play a role in neoplastic 
transformation in several human tissues [6–10]. In particular, the genes belonging to HOX paralogous 
group 13 seem to carry out a relevant role in both tumor development and progression.  
We have identified a significant prognostic role of HOX D13 in pancreatic cancer [11] and the HOX 
A13 gene deregulation in liver carcinogenesis [12]. The amplification of 12q13–15 locus, containing 
HOX C13 gene, was associated with a large number of cancers such as sarcomas, glioblastomas, lung, 
bladder and transitional carcinomas and melanomas [13–20]. Moreover, we have recently showed the 
strong and progressive over-expression of HOX C13 in melanoma metastases when compared to nevi 
and primary melanomas, suggesting its role in a metastatic melanoma switch [21]. We have also 
showed the aberrant expression of HOX B13 in bladder tumorigenesis and progression [22]. 
In this study we have analyzed paralogous 13 HOX genes expression, by immunohistochemistry and 
real time PCR, in non-neoplastic thyroid samples, in a case series of thyroid cancer histotypes and in 
the corresponding lymph nodal metastases, highlighting a potential role of these genes in thyroid 
cancer evolution.  
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2. Results 
2.1. Clinic Pathological Characteristics of Thyroid Cancers and Patients 
In our series of tissue samples, 50 specimens of thyroid cancers and 12 normal thyroid tissues as 
controls are included. Tumor samples comprised two main histotypes: classical papillary carcinoma 
(CPC) (50%), follicular variant papillary carcinoma (FPC) (32%), and follicular carcinoma (FC) (13%).  
Female patients were 38 out of 50 (76%), while male were 12 (24%). The age range was 13–74 years, 
with an average of 43 years. Regarding the staging, 58% was stage I, 4% stage II, 26% stage III, and 
13% stage IV. The details of clinic-pathological data are shown in Table 1. 
Table 1. Clinic pathological features of thyroid cancer patients.  
Gender M 12 (24) 
F 38 (76) 
Age <=45 29 (58) 
46+ 21 (42) 
HISTOTYPE CPC 26 (52) 
FPC 17 (34) 
FC 7 (14) 
STAGE I 29 (58) 
II 2 (4) 
III 13 (26) 
IV 6 (12) 
2.2. Paralogous 13 HOX Genes Expression in Thyroid Cancer Histotypes 
HOX A13, HOX B13, HOX C13 and HOX D13 expressions were detected by immunohistochemistry 
on t-MTA. We considered both nuclear and cytoplasmic positivity for statistical associations. In general, 
tumor samples stained more consistently for paralogous 13 HOX genes than their normal counterpart 
(normal tissues and adenomas) (Figure 1).  
All IHC HOX expression data were statistically analyzed and all statistical elaborations are schematized 
in (Table S1) and represented in graphic form in Figure 2.  
Aberrant HOX A13 nuclear expression appeared strongly associated (p < 0.001) to different 
histotypes of thyroid cancer. Its expression gradually increased from adenoma, to CPC, to FPC, until FC. 
The opposite trend characterized HOX B13, a significant decreasing (p = 0.0013) of nuclear expression 
in the transition from non-neoplastic tissues to different tumor histologic types. Regarding HOX C13, 
both nuclear (p = 0.0021) and cytoplasmic (p = 0.0013) expression were significant, with a trend of 
increasing from the normal thyroid to the adenoma and to cancer histologic types, except for a reverse 
trend of the only nuclear expression in FC histotype. Finally, a strong statistical significance was 
shown for cytoplasmic expression (p < 0.001) of HOX D13, that gradually increased from normal 
tissues, to adenoma, to CPC, to FPC, until FC.  
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Figure 1. Paralogous group 13 HOX genes IHC expression in thyroid samples: (A) HOX 
A13 expression in normal tissue (40×); (B) HOX A13 expression in adenoma (40×);  
(C) HOX A13 expression in CPC histotype (40×); (D) HOX A13 expression in  
FC histotype (40×); (E) HOX B13 expression in normal tissue (40×); (F) HOX B13 
expression in adenoma (40×); (G) HOX B13 expression in CPC histotype (40×);  
(H) HOX B13 expression in FC histotype (40×); (I) HOX C13 expression in normal  
tissue (40×); (J) HOX C13 expression in adenoma (40×); (K) HOX C13 expression in  
CPC histotype (40×); (L) HOX C13 expression in FC histotype (40×);  
(M) HOX D13 expression in normal tissue (40×); (N) HOX D13 expression in adenoma 
(40×); (O) HOX D13 expression in CPC histotype (40×); (P) HOX D13 expression in FC 
histotype (40×).  
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Figure 2. Plot graphic representation of paralogous group 13 HOX genes IHC expression 
in thyroid samples: (1,2) Nuclear (on the left) and cytoplasmic (on the right) HOX A13 
expression; (3,4) Nuclear (on the left) and cytoplasmic (on the right) HOX B13 
expression; (5,6) Nuclear (on the left) and cytoplasmic (on the right) HOX C13 expression; 
(7,8) Nuclear (on the left) and cytoplasmic (on the right) HOX D13 expression  
(* and ° indicate values off the graph).  
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The comparison between the nuclear and cytoplasmic expression between 4 markers, associated in 
pairs, showed a predominant tendency to cytoplasmic localization as shown in Table 2. The detail of 
the trends of expression is shown in Table S2. 
Paralogous 13 HOX genes expression was also detected by real time PCR on 10 thyroid samples,  
2 adenoma, 4 CPC, 2 FPC, and 2 FC histotypes.  
A trend of increasing expression was observed between non-neoplastic tissues and various thyroid 
tumor histotypes, as showed by immunohistochemical analysis. In particular, normal tissue and adenoma 
showed a low or absent expression (between 0–10 fold expression) particularly for HOX A13, HOX 
C13 and HOX D13, whereas, in all tumor samples an increased expression was detected (between  
100–1000 fold expression). Moreover, for HOX B13 no significant differences were present between 
adenoma and CPC histotype with a moderate expression (between 10–100 fold expression), while FC 
histotype showed a low expression (between 0–10 fold expression) (Figure 3). 
Table 2. Cytoplasmic versus nuclear expression distribution of HOX A13, HOX B13, HOX 
C13 and HOX D13. Wilcoxon Signed Ranks Test. 
Wilcoxon Signed Ranks Test 
Ranks N p-Value 
HOX A13 
Cytoplamic_Expression < Nuclear_Expression 57 <0.001 
Cytoplamic_Expression > Nuclear_Expression 1 
Cytoplamic_Expression = Nuclear_Expression 4   
HOX B13 
Cytoplasmic_Expression < Nuclear_Expression 3 <0.001 
Cytoplasmic_Expression > Nuclear_Expression 47 
Cytoplasmic_Expression = Nuclear_Expression 12   
HOX C13 
Cytoplasmic_Expression < Nuclear_Expression 21 0.19 
Cytoplasmic_Expression > Nuclear_Expression 29 
Cytoplasmic_Expression = Nuclear_Expression 13   
HOX D13 
Cytoplasmic_Expression < Nuclear_Expression 4 <0.001 
Cytoplasmic_Expression > Nuclear_Expression 50 
Cytoplasmic_Expression = Nuclear_Expression 9   
2.3. Paralogous 13 HOX Genes Expression in Papillary and Follicular Thyroid Cancer Progression  
Nuclear and cytoplasmic HOX expression was detected by immunohistochemistry and statistically 
analysed on thyroid samples for which we had primary tumors and corresponding lymph node 
metastases (Figure 4). 
All IHC results statistically elaborated, are shown in Table S3, but no significant association has 
been found. 
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Figure 3. Real Time PCR expression of HOX A13, HOX B13, HOX C13 and HOX D13 
genes in thyroid tissue samples. All reactions were performed in triplicate and data are 
expressed as mean of relative amount of mRNAs levels.  
 
Figure 4. Paralogous group 13 HOX genes IHC expression in metastatic thyroid samples: 
(A) HOX A13 expression (40×); (B) HOX B13 expression (40×); (C) HOX C13 expression 
(40×); (D) HOX D13 expression (40×).  
 
3. Discussion 
Various evidence associating the altered expression of many HOX genes to cancerogenesis have 
previously been shown [8].  
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In this study we have focused attention on HOX genes of paralogous group 13, with activity correlated 
to cell proliferation, and for which deregulation is often associated with tumor evolution [11,12,21–25].  
Genes posteriorly located in the HOX network (paralogous 13 HOX genes) are responsible of the correct 
formation of limbs and urogenital structures during the normal development. When mutated, they can 
generate life-compatible phenotypes, such as synpolydactyly and hand-foot-genital syndrome [26,27]. 
Among paralogous 13 HOX genes, HOX A13 expression has been associated to enhance tumor 
growth in vitro, and in vivo to tumor-node-metastasis (TNM) stage and disease-free survival time of 
patients with esophageal squamous cell carcinoma (ESCC) [28]. Moreover, its overexpression has been 
detected in primary hepatocarcinoma and versus non-tumorous livers [12]. Recently, an up-regulation 
of HOXA13 expression has been associated with highly aggressive forms of gastric cancer, 
highlighting its prognostic role also in this type of cancer [29].  
HOX B13 has been associated with tumor evolution and progression of several hormone-dependent 
tumors, as prostate, ovary and breast cancers [30–32]. Recently, a rare, recurrent mutation (G84E) in 
HOX B13 was reported to be associated with prostate cancer risk [33]; its aberrant expression was also 
shown in melanoma, cervical and colon cancers [34–36]. Finally, we recently showed that HOX B13 
aberrant expression might better stratify patients with non-muscle invasive bladder cancers (NMIBCs) 
at risk of recurrence [22]. Posterior locus C HOX genes have been associated to bladder and renal  
cancer [37,38] and the strong and progressive over-expression of HOX C13 in melanoma metastases 
has suggested its potential role in metastatic melanoma switch [21]. Finally, HOX D13 deregulation 
has been reported in several human cancers, and its aberrant expression was strongly associated to 
pancreatic cancer development and progression [11]. 
However, there are few suggestions about the role of HOX genes in the development and progression 
of thyroid tumors based on cellular models [39]. Although thyroid papillary cancer generally manifests 
an indolent biologic behaviour, it exhibits, as FC histotype, a high degree of genomic instability [40], 
particularly chromosome rearrangements, [41] gene mutations [42] and de-regulation of many subsets of 
molecules, especially transcription factors [43–45]. Several studies have demonstrated that all these 
genetic alterations represent molecular prognosticators for these types of tumor.  
We have analyzed paralogous 13 HOX genes expression in adenoma, CPC and FC thyroid histotypes. 
Our data showed, both at protein and gene level, an aberrant expression of genes of paralogous 13 in 
thyroid cancers. In fact, the four markers appear differently expressed in adenoma versus CPC 
(mainly) and FC histotypes, and between the two main histological tumor types.  
Even if the two expression profiles are often not comparable, our immunohistochemistry data were 
confirmed by qRT-PCR, and this has allowed us to suggest that alterations in HOX expression are 
found at both the gene and protein level.  
Moreover, we selected a case series of thyroid cancers with corresponding lymph nodal metastases, 
to analyze paralogous 13 HOX genes expression and to verify if the aberrant expression of these genes 
could also be associated with tumor progression. However, all paralogous 13 HOX genes were not 
significantly associated to lymph node metastases during thyroid tumor progression. 
In our study we have separately considered nuclear and cytoplasmic HOX protein expressions. In 
fact, in most of the studies performed through immunohistochemistry, HOX proteins expression in the 
cytoplasm was often reported [8], nuclear expression was considered indicative, being transcriptional 
regulators [13].  
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The overall analysis of our data has indicated a trend of the four markers predominantly localized in 
the cytoplasm. The ability of these genes to present a cytoplasmic localization was already described in 
several tissues, during development [46], and in cancer [23]. In some types of cancer this different sub 
cellular localization has represented an unfavorable prognostic factor in tumor progression [23,25]. 
The different expressions, nuclear and cytoplasmic, of the 4 markers, were crossed with each other, 
showing a specific trend for the adenoma and for the two tumor histotypes.  
In particular, the nuclear positivity of HOX A13 and HOX B13 showed an opposite trend in the 
transition from adenoma to cancer.  
The differential diagnosis between adenomas and thyroid tumors often represents an important 
diagnostic problem. The use of HOX A13 and HOX B13 could suggest a clinical application, as a 
useful diagnostic tool, especially for cytological diagnosis.  
4. Methods 
4.1. Thyroid Cancer Patients  
Fifty patients admitted to the National Cancer Institute “Giovanni Pascale” of Naples, between 
2008 and 2011, were recruited in this study. All patients provided written informed consent for the use 
of samples according to the institutional regulations, and the study was approved by the ethics 
committee of the National Cancer Institute “G. Pascale”.  
Normal and adenoma thyroid tissues and cells were used as non-neoplastic controls. All tumour 
cases have been reviewed according to WHO/ISUP 2007 classification criteria, using standard tissue 
sections. Medical records have been reviewed for clinical information, including histologic parameters 
assessed on standard H & E-stained slides. 
4.2. TMAs Building  
A thyroid Multi-Tumor Array (t-MTA) was constructed using 50 tumor tissue samples (7 FC and 
43 CPC histotypes) and 12 non-neoplastic tissues samples (6 normal and 6 adenoma). The 
corresponding lymph node metastases for 14 samples from this series were also available. The most 
representative areas of surgical samples blocks were used for TMA construction. All tumors and 
controls were reviewed by two experienced pathologists (RF and SL). Discrepancies for the same case 
were resolved in a joint analysis. Tissue cylinders with a diameter of 1 mm were punched from 
morphologically representative tissue areas of each “donor” tissue block and brought into one recipient 
paraffin block (3 × 2.5 cm) using a semi-automated tissue arrayer (Galileo TMA, Integrated Systems 
Engineering, Milano, Italy). 
4.3. Immunohistochemistry Analysis  
Immunohistochemical staining was carried out on slides from formalin-fixed, paraffin embedded 
tissues, in order to evaluate the expression of HOX A13, HOX B13, HOX C13 and HOX D13. Paraffin 
slides was then deparaffinized in xylene and rehydrated through graded alcohols. Antigen retrieval was 
performed with slides heated in 0.01 M citrate buffer (pH 6.0) in a bath for 20 min at 97 °C. After 
antigen retrieval, the slides were allowed to cool. The slides were rinsed with TBS and the endogenous 
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peroxidase has inactivated with 3% hydrogen peroxide. After protein block (BSA 5% in PBS 1×), the 
slides were incubated with primary antibody to human HOX A13 (dilution 1:200, cod. Ab106503, Abcam, 
Cambridge, UK), HOX B13 (dilution 1:300, cod. ab28575, Abcam, Cambridge, UK), HOX C13 
(dilution 1:1200, cod.ab55251, Abcam, Cambridge, UK), HOX D13 (dilution 1:100, cod. Ab19866, 
Abcam, Cambridge, UK) overnight. Sections were incubated with mouse anti-rabbit or goat anti-mouse 
secondary IgG biotinylated secondary antibody for 30 min. Immunoreactivity was visualized by means 
of avidin-biotin-peroxidase complex kit reagents (Novocastra, Newcastle, UK) as the chromogenic 
substrate. Finally, sections were weakly counterstained with haematoxylin and mounted. 
4.4. Evaluation of Immunostaining 
Antigen expression was independently evaluated by two experienced pathologists (RF/SL) using 
light microscopy. For paralogous 13 HOX genes, nuclear and cytoplasmic localization were considered. 
All values of immunostaining were expressed only in percentage terms of positive cells. The percentage 
of positive cancer cells was evaluated in each sample by counting the number of positive cells over the 
total cancer cells in 10 non-overlapping fields using ×400 magnification.  
4.5. RNA Extraction and Analysis 
Total RNA was isolated from 10 thyroid samples: 2 adenoma, 4 primary CPC, 2 FPC, and 2 FC 
histotypes. FFPE samples were collected from the National Cancer Institute “Fondazione G. Pascale” 
Institutional Bio-Bank. High pure FFPE RNA Micro Kit (Roche Molecular Biochemicals, Mannheim, 
Germany) was used for FFPE specimens following the manufacturer’s instructions. A total of 1 μg 
RNA was subjected to cDNA synthesis for 1 h at 37 °C using the Ready To Go You-Primer  
First-Strand Beads kit (Amersham Biosciences Europe Gmbh, Freiburg, Germany, cod.27-9264-01) in 
a reaction mixture containing 0.5 μg random hexamers (GeneAmp RNA PCR Random Hexamers Set 
N808-0127 Applied Biosystems, Foster City, CA, USA). 
4.6. Quantitative Real-Time PCR  
Quantitative RT-PCR was performed in a LightCycler system (Roche Molecular Biochemicals, 
Mannheim, Germany) using TaqMan® analysis. In this system, all reactions have been run in glass 
capillaries in a volume of 20 μL with 4 μL of The LightCyclerTaqMan Master Mix (cod. 04735536001, 
Roche Molecular Biochemicals, Rotkreuz, Switzerland), 2 μL of cDNA and 1 μL of specific TaqMan 
Gene Expression Assays for human HOX A13, HOX B13, HOX C13, HOX D13 (RealTime Designer Assay 
cod.05583055001, Roche Molecular Biochemicals, Rotkreuz, Switzerland) according to the manufacturer’s 
directions. All reactions were performed in triplicate. The thermal cycling conditions included a step of 
20 s at 95 °C followed by a 40 cycles of 95 °C for 1 s and 60°C for 20 s. The comparative Ct method 
was employed to determine the human HOX genes variation, using TaqMan Endogenous Controls 
Human ACTB (β-actin) Endogenous Control (Real Time Designer Assay cod.05532957001, Roche 
Molecular Biochemicals, Rotkreuz, Switzerland) as reference gene. Final amounts of target were 
determined as follows: target amount = 2 − Ct where Ct = [Ct (HOX genes) − Ct (ACTB)]sample −  
[Ct (HOX genes) − Ct (ACTB)]calibrator. Data were expressed as mean ± standard deviation (SD, n = 3). 
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4.7. Statistical Analysis 
Only a percentage of immunoreactive cells were considered for the evaluation of paralogous HOX 
13 IHC expression on t-MTA, encopassing different hystotypes.  
The Kruskal-Wallis test was applied to identify differences in median expression values of each marker 
among the five groups of thyroid cancer considered (normal, adenoma, CPC, FPC and FC tissues). 
All calculations were performed using the MedCalc 12.7 software (MedCalc Software, Acacialaan 22, 
B-8400 Ostend, Belgium) and results were considered statistically significant when p-value was ≤0.05. 
The statistical analysis was carried out considering nuclear and cytoplasmic protein expression. 
The Wilcoxon signed-rank test was used to study the correlation between the nuclear and cytoplasmic 
expression in the HOX 13 paralogous group genes because of nonparametric and paired values. 
5. Conclusions 
Cytological evaluation is the first approach to thyroid nodules and most cases are easily categorized 
as benign or malignant through simple morphology. Differential diagnosis of benign and malignant 
nodules is sometime however, very difficult, particularly in cytological smears with a clear follicular 
pattern and patients are subjected to thyroid lobectomy. Thus, the use of HOX A13 and HOX B13 
expression could enormously help in differential diagnosis of cytologic samples. Its use could also be 
applied on histological samples, in the definition of well differentiated neoplasias not easily defined as 
benign or malignant.  
Our data may represent an important element for the development of potential therapies targeted 
against the activities of HOX genes. In fact, antisense oligonucleotide (ASO), small interfering RNA 
(siRNA) [47] and post-translational interaction between HOX proteins and their PBX cofactors, able to 
block both in vivo and in vitro tumor cell growth and proliferation, have been recently described [47].  
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